NEW YORK (S&P Global Ratings) Jan. 21, 2021--S&P Global Ratings said today that Boston Scientific Corp.'s (BBB-/Stable/A-3)recently announced acquisition of Preventice Solutions Inc.--for $720 million in cash up front (net of Boston Scientific's equity ownership) and up to $230 million in potential milestone payments--is comfortably within the company's leverage capacity for 2021. We expect Boston Scientific's leverage to be about 4x in 2020 and improve to the mid-3x area by year-end 2021. Preventice Solutions specializes in mobile cardiac health solutions and services, which we see as a good strategic fit for Boston Scientific. Despite the adversities of the COVID-19 pandemic, Boston Scientific's liquidity and leverage positions remained solid through 2020 after it issued $2 billion in equity in May 2020,
